Results 41 to 50 of about 12,380 (194)

Effects of Clopidogrel, Prasugrel and Ticagrelor on Microvascular Function and Platelet Reactivity in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Stenting. A Randomized, Blinded, Parallel Group Trial

open access: yesFrontiers in Cardiovascular Medicine, 2021
Aims: In this pre-specified analysis of the “endothelium, stent and antiplatelet therapy” study, we investigate the impact of antiplatelet therapies on microvascular function in patients undergoing stenting for an acute coronary syndrome.Methods and ...
Boris Schnorbus   +7 more
doaj   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

open access: yesBritish Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk   +2 more
wiley   +1 more source

AN EXTENSIVE REVIEW ON PRASUGREL

open access: yes, 2018
In an attempt prasugrel increase in the overall use of this medication comparing to the anti thembolytics like heparin and wararin, with less patients complaints includes side effects a significant portion of patients receiving the medication for off ...
Nagaraju, GV   +2 more
core   +2 more sources

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

open access: yesJournal of Diabetes Investigation, EarlyView.
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi   +4 more
wiley   +1 more source

Prasugrel in critically ill patients

open access: yes, 2017
SummaryWhile prasugrel is indicated for the treatment of myocardial infarction, its effects in the most severely affected patients requiring intensive care is unknown, so that we measured the antiplatelet effects and sparse pharmacokinetics of prasugrel ...
Gottfried Heinz   +9 more
core   +1 more source

Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis

open access: yesHealth Technology Assessment, 2015
Background: Acute coronary syndromes (ACSs) are life-threatening conditions associated with acute myocardial ischaemia. There are three main types of ACS: ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (
Janette Greenhalgh   +9 more
doaj   +1 more source

Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.

open access: yes, 2015
OBJECTIVE To assess safety up to 1 year of follow-up associated with prasugrel and clopidogrel use in a prospective cohort of patients with acute coronary syndromes (ACS).
Roffi, Marco   +45 more
core   +1 more source

Influence of the Residual Gensini Score on Prognosis of Patients With ST‐Elevation Myocardial Infarction

open access: yesCatheterization and Cardiovascular Interventions, Volume 108, Issue 1, Page 76-83, July 1, 2026.
ABSTRACT Background The residual Gensini score (rGS) was developed to quantify the severity of coronary atheroma burden after coronary revascularisation. The predictive value of the rGS for clinical outcomes in patients with ST‐segment elevation myocardial infarction (STEMI) remains unexplored.
Batric Popovic   +8 more
wiley   +1 more source

Safety of Prasugrel in Indian patients – Multicentric registry of 1000 cases

open access: yesIndian Heart Journal, 2014
Background: Clopidogrel has been the only available antiplatelet drug used along with aspirin in patients of ACS. In recent years 2 new antiplatelet drugs (Prasugrel and Ticagrelor) have become available.
Upendra Kaul   +14 more
doaj   +1 more source

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.

open access: yesPLoS ONE, 2015
BackgroundPrasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary syndromes. Data available on prasugrel reloading in clopidogrel treated patients with high residual platelet reactivity (HRPR) i.e. poor responders,
Tobias Geisler   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy